-
May 31, 2018 Lupin appoints Nicholas Hart as President – Specialty for US Business
-
May 25, 2018 Lupin submits Marketing Authorization Application for Etanercept Biosimilar in Europe
-
May 15, 2018 Lupin announces fiscal year 2018 Results, Board recommends dividend of 250%
-
May 14, 2018 Lupin’s Nagpur facility US FDA inspection concluded with no observations
-
May 10, 2018 Lupin launches Corcal Bone and Beauty supplement
-
May 8, 2018 Lupin submits New Drug Application for Etanercept biosimilar in Japan
-
May 7, 2018 Lupin receives FDA approval for generic Temovate Ointment, 0.05%
-
April 23, 2018 Lupin receives FDA approval for generic Xenazine® Tablets, 12.5 mg and 25 mg
-
April 17, 2018 Lupin receives tentative FDA approval for generic AndroGel®, 1.62%
In this section
Media Contacts
-
Rajalakshmi Azariah
Vice President & Global Head – Corporate Communications